Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Claim 1
Document A
Document B
1.1A crystal form of a compound of Formula (I), selected from at least one of crystal form I, crystal form II, crystal form III, crystal form IV, crystal form V, crystal form VI, or crystal form VII
With regard to the tetomilast hydrate crystal, anhydrous tetomilast type A crystal, anhydrous tetomilast type C crystal, tetomilast acetonitrile solvate crystal, and a mixture of the above anhydrous tetomilast type A crystal and an anhydrous tetomilast type B crystal of the present invention, the crystal forms thereof are easily controlled by recrystallization, and these crystals are excellent in terms of filterability.
B · US 9,145,404 B2 · ¶ 1941.2wherein, there are diffraction peaks at 2θ of 10.0, 10.6, 11.5, 12.1, 14.1, 16.7, 17.4, 19.0, 19.4, 20.5, 21.9, 24.9 (±0.2°) in an X-ray powder diffraction (XRPD) pattern of the crystal form I of the compound of Formula (I)
Specifically, it has characteristic peaks at 2θ=10.6°, 12.9°, 21.1°, 22.3°, and 25.0°.
B · US 9,145,404 B2 · ¶ 291.3further, there are additional diffraction peaks at 2θ of 13.4, 14.5, 17.8, 18.7, 20.0, 21.1, 22.8, 23.8, 26.0, 26.9 (±0.2°) in the XRPD pattern of the crystal form I of the compound of Formula (I)
1.4further, the diffraction peak profile in the XRPD pattern of the crystal form I of the compound of Formula (I) is as shown in the table below: No. 2θ (±0.2°) 1 10.0 2 10.6 3 11.5 4 12.1 5 13.4 6 14.1 7 14.5 8 16.7 9 17.4 10 17.8 11 18.7 12 19.0 13 19.4 14 20.0 15 20.5 16 21.1 17 21.9 18 22.8 19 23.8 20 24.3 21 24.9 22 25.4 23 26.0 24 26.9 25 27.3 26 28.3 27 28.7 28 29.2 29 29.9 and further, the XRPD pattern of the crystal form I of the compound of Formula (I) is essentially as shown in FIG. 1
The synthetic porous crystalline material of this invention, MCM-65, is a single crystalline phase which, in its calcined form, has an X-ray diffraction pattern which is distinguished from the patterns of other known as-synthesized or thermally treated crystalline materials by the lines listed in Table 1 below.
A · US 6,869,587 B2 · ¶ 19(2) The monohydrate crystal has a powder X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in FIG. 2. Specifically, it has characteristic peaks at 2θ=10.6°, 12.9°, 21.1°, 22.3°, and 25.0°.
B · US 9,145,404 B2 · ¶ 291.5wherein, there are diffraction peaks at 2θ of 10.9, 12.1, 16.1, 17.0, 17.5, 18.3, 23.4 (±0.2°) in an X-ray powder diffraction (XRPD) pattern of the crystal form II of the compound of Formula (I)
A process for the preparation of an anhydrous tetomilast type C crystal as defined in claim 1 or 2, which is characterized in that it comprises recrystallization from a solution formed by dissolving an anhydrous tetomilast type B crystal in a solvent wherein said anhydrous tetomilast type B crystal has a powder X-ray diffraction spectrum having characteristic peaks at 2θ=4.1°, 8.1°, 11.9°, 16.1° and 24.2°.
B · US 9,145,404 B2 · claim 61.6further, the diffraction peak profile in the XRPD pattern of the crystal form II of the compound of Formula (I) is as shown in the table below: No. 2θ (±0.2°) 1 10.9 2 12.1 3 16.1 4 17.0 5 17.5 6 18.3 7 23.4 and further, the XRPD pattern of the crystal form II of the compound of Formula (I) is essentially as shown in FIG. 5
1.7wherein, there are diffraction peaks at 2θ of 6.1, 10.6, 12.3, 16.6, 17.9, 18.7 (±0.2°) in an X-ray powder diffraction (XRPD) pattern of the crystal form III of the compound of Formula (I)
1.8further, the diffraction peak profile in the XRPD pattern of the crystal form III of the compound of Formula (I) is as shown in the table below: No. 2θ (±0.2°) 1 6.1 2 10.6 3 12.3 4 16.6 5 17.9 6 18.7 and further, the XRPD pattern of the crystal form III of the compound of Formula (I) is essentially as shown in FIG. 8
1.9wherein, there are diffraction peaks at 2θ of 6.2, 8.1, 10.7, 16.4, 17.1, 18.6, 19.4, 21.3 (±0.2°) in an X-ray powder diffraction (XRPD) pattern of the crystal form IV of the compound of Formula (I)
1.10further, there are additional diffraction peaks at 2θ of 7.1, 11.2, 16.7, 17.7, 18.8, 19.8, 20.4, 22.0, 22.3, 22.5, 23.1, 24.7 (±0.2°) in the XRPD pattern of the crystal form IV of the compound of Formula (I)
1.11further, the diffraction peak profile in the XRPD pattern of the crystal form IV of the compound of Formula (I) is as shown in the table below: No. 2θ (±0.2°) 1 6.2 2 7.1 3 8.1 4 10.7 5 11.2 6 11.9 7 12.8 8 13.4 9 14.1 10 16.4 11 16.7 12 17.1 13 17.7 14 18.6 15 18.8 16 19.4 17 19.8 18 20.4 19 21.3 20 22.0 21 22.3 22 22.5 23 23.1 24 24.7 25 27.0 26 28.4 and further, the XRPD pattern of the crystal form IV of the compound of Formula (I) is essentially as shown in FIG. 12
1.12wherein, there are diffraction peaks at 2θ of 6.2, 8.1, 10.6, 16.2, 18.5, 19.1 (±0.2°) in an X-ray powder diffraction (XRPD) pattern of the crystal form V of the compound of Formula (I) further, the diffraction peak profile in the XRPD pattern of the crystal form V of the compound of Formula (I) is as shown in the table below: No. 2θ (±0.2°) 1 6.2 2 8.1 3 10.6 4 16.2 5 18.5 6 19.1 and further, the XRPD pattern of the crystal form V of the compound of Formula (I) is essentially as shown in FIG. 16 wherein, there are diffraction peaks at 2θ of 5.5, 5.8, 10.7, 16.9, 17.9, 18.3 (±0.2°) in an X-ray powder diffraction (XRPD) pattern of the crystal form VI of the compound of Formula (I) further, there are additional diffraction peaks at 2θ of 9.1, 10.4, 15.9, 20.0, 20.9, 21.6 (±0.2°) in the XRPD pattern of the crystal form VI of the compound of Formula (I) further, the diffraction peak profile in the XRPD pattern of the crystal form VI of the compound of Formula (I) is as shown in the table below: No. 2θ (±0.2°) 1 5.5 2 5.8 3 9.1 4 10.4 5 10.7 6 15.9 7 16.9 8 17.9 9 18.3 10 20.0 11 20.9 12 21.6 and further, the XRPD pattern of the crystal form VI of the compound of Formula (I) is essentially as shown in FIG. 20 wherein, there are diffraction peaks at 2θ of 6.3, 10.9 (±0.2°) in an X-ray powder diffraction (XRPD) pattern of the crystal form VII of the compound of Formula (I) further, the XRPD pattern of the crystal form VII of the compound of Formula (I) is essentially as shown in FIG. 23.
A process for the preparation of an anhydrous tetomilast type C crystal as defined in claim 1 or 2, which is characterized in that it comprises recrystallization from a solution formed by dissolving in a solvent at least one type of tetomilast crystal selected from the group consisting of a tetomilast hydrate crystal having a powder x-ray diffraction spectrum having characteristic peaks 2θ=10.6°, 12.9°, 21.1°, 22.3° and 25.0°, an anhydrous tetomilast type A crystal having a p
B · US 9,145,404 B2 · claim 8An empty cell means only that no passage was reproduced there.